Quarterly ResultMay 15, 2026, 07:56 AM
Galectin Therapeutics Reports Q1 2026 Results; Belapectin Program Advances
AI Summary
Galectin Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2026, alongside a business update on its belapectin program. The company announced a net loss of $5.1 million, or ($0.08) per share, and held $14.1 million in cash and cash equivalents, with a projected cash runway through May 2027. Key updates for the belapectin program included additional positive analyses from the NAVIGATE trial, showing statistically significant reductions in liver stiffness and a reduction in disease progression for MASH cirrhosis patients. The company anticipates upcoming data presentations at EASL and a Type-C meeting with the FDA in Q2 2026.
Key Highlights
- Net loss applicable to common stockholders was $5.1 million, or ($0.08) per share, for Q1 2026.
- Cash and cash equivalents totaled $14.1 million as of March 31, 2026.
- Company has sufficient cash to fund planned operations and R&D activities through May 2027.
- Research and development expenses decreased to $2.2 million in Q1 2026 from $6.5 million in Q1 2025.
- General and administrative expenses increased to $1.8 million in Q1 2026 from $1.4 million in Q1 2025.
- Belapectin 2 mg/kg arm showed statistically significant reductions in liver stiffness at Weeks 26, 52, and 78.
- Treatment with belapectin reduced clinically meaningful worsening in liver stiffness (11.7% vs. 23.9% for placebo; p=0.03).
Price Impact
More from GALT